BEHOLD-1

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Mar 19, 2026 → Oct 29, 2026

Cited window

Mar 19, 2026 → Oct 29, 2026

Retrieved

Oct 31, 2026

Title

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Subjects With Advanced Solid Tumors

Registry

NCT06431594

Study IDs

222730 · 2024-513860-25 (CTIS)

Sponsor

GlaxoSmithKline

Design

Phase 1 · Interventional, randomized, sequential

Status

Recruiting

Enrollment

675 estimated

Registered

2024-05-28

Start

2024-07-02 actual

Primary completion

2027-09-22 estimated

Primary endpoint

Part 1: Number of participants with dose limiting toxicity (DLT)

Interventions

1 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –2 cited commentary passages leave a source question open, such as who was speaking. The report attributes no further than the source shows.
• –Not yet captured in this edition: a question about safety concerns when choosing an alternative antibody–drug conjugate for advanced endometrial cancer.
• –Not yet captured in this edition: a question about ADC payload selection and community management of payload-related toxicities.
• –Not yet captured in this edition: a view on prior toxicity-management experience and the lack of focused mitigation strategies in gynecologic oncology.
• –Not yet captured in this edition: a view on choosing immunotherapy versus an antibody–drug conjugate according to performance status, response urgency and symptomatic disease burden.
• –Not yet captured in this edition: a view on the tentative comparative positioning of antibody–drug conjugates and their sequencing in advanced gynecologic cancers.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –70 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits apply, so some matching discussion may be missing.
• –This is a selective account of the sources reviewed for this edition, not a representative sample of HCP opinion or evidence of consensus.
• –The search emphasized BEHOLD-1 and listed drug names. Unnamed references, different transcriptions and discussions that could not be read or fully evaluated may be missing.
• –Some potentially relevant treatment-selection and counseling passages are not represented in the verified statements available here. A complete account of alternative-ADC counseling or conditional decisions to defer treatment cannot be inferred.
• –The publication provided is a methods and endpoints description, not a results publication independently validating the response, durability or safety figures discussed. A full protocol and an exact product label were unavailable.
• –Several results are relayed from presentations or sponsor announcements. Their ownership remains with the attributed party; favorable reporting is not an independent clinical endorsement.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –A speaker is described in the source as presenting BEHOLD-1. That involvement is source-described and should accompany interpretation of the interview, rather than being treated as an external independent assessment.
• –Some passages cannot be reliably assigned a speaker name and may be by named participants in the same source. Repeated videos, reposts and organizational relays do not establish additional independent HCP views.
• –Dose-specific, disease-specific and supportive-care-qualified accounts should not be pooled. Publication or post dates alone do not establish a change of mind, a changed dose decision or improved safety.

How reports are built and checked: Methods.

Last checked for new commentary Oct 31, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "BEHOLD-1" (NCT06431594), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "behold-1-06431594". If you cannot make requests, read https://www.erudio.com/reports/behold-1-nct06431594.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT06431594", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct06431594 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/behold-1-nct06431594.json
curl https://www.erudio.com/reports/behold-1-nct06431594.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "behold-1-06431594" })